Bromfenac versus betamethasone in diabetic macular oedema
31 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, betamethasone, bromfenac, central subfield thickness, intraocular pressure
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
Effect of heredity on risk of diabetic retinopathy
1 September 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, heredity, proliferative diabetic retinopathy, risk factors, survival analysis
This study used survival analysis on 2199 patients who had reached vision-threatening diabetic retinopathy to investigate the contribution of heredity to diabetes together with other known risk factors for the development of either proliferative diabetic retinopathy (PDR) or diabetic macular...
Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection
3 April 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Dexamethasone implant, Diabetic macular edema, Pars plana vitrectomy, Posterior subtenon triamcinolone
This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...
Cystoid macular oedema following retinal detachment surgery
5 April 2022
| Kurt Spiteri Cornish
|
EYE - Cataract, EYE - Refractive
|
Cystoid macular edema, rhegmatogenous retinal detachment, vitreoretinal surgery
There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...
OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
1 December 2021
| Su Young
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, aflibercept, optical coherence tomography, predictive, ranibizumab
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....
Outcomes of treat & extend ranibizumab in diabetic macular oedema
1 October 2021
| Ed Rule
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, Outcome predictor, Ranibizumab, Spectral-domain optical coherence tomography, Treat and extend
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...
Steroid treatment for pseudophakic cystoid macular oedema
1 October 2021
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Cystoid macular edema, intravitreal steroids, triamcinolone
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Management of diabetic macular oedema (DMO)
1 February 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
